Publicaciones en colaboración con investigadores/as de University of Pennsylvania (13)

2024

  1. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer treated with niraparib vs placebo: Results from the phase 3 randomized PRIMA/ENGOT-OV26/GOG-3012 trial

    Gynecologic Oncology, Vol. 184, pp. 168-177

2022

  1. Complement C5a induces the formation of neutrophil extracellular traps by myeloid-derived suppressor cells to promote metastasis

    Cancer Letters, Vol. 529, pp. 70-84

2020

  1. Niraparib in Patients With Newly Diagnosed Advanced Ovarian Cancer

    Obstetrical and Gynecological Survey

  2. Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer

    Gynecologic Oncology, Vol. 157, Núm. 2, pp. 379-385

2019

  1. Author Correction: ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development (Nature Immunology, (2019), 20, 11, (1409-1413), 10.1038/s41590-019-0503-1)

    Nature Immunology

  2. Complementing the cancer-immunity cycle

    Frontiers in Immunology, Vol. 10, Núm. APR

  3. Niraparib in patients with newly diagnosed advanced ovarian cancer

    New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2391-2402

  4. ‘Stealth’ corporate innovation: an emerging threat for therapeutic drug development

    Nature Immunology

2014

  1. The role of complement in tumor growth

    Advances in Experimental Medicine and Biology

2013

  1. Complement inhibition in cancer therapy

    Seminars in Immunology, Vol. 25, Núm. 1, pp. 54-64

  2. Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: An individual patient data meta-analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 87, Núm. 4, pp. 690-696

  3. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: An international individual patient data meta-analysis

    International Journal of Radiation Oncology Biology Physics, Vol. 85, Núm. 2, pp. 444-450

2012

  1. Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression

    Journal of Immunology, Vol. 189, Núm. 9, pp. 4674-4683